Craig Basson tells us why he leapt from NIBR to Boston Pharma; Ex-BMS Partner CytomX finds new CMO in Allison Hannah
Senior year, Craig Basson would walk to the storeroom in Roslyn High and check on the rats his science teacher had ordered him.
The experiment was simple. Basson castrated the rats. He waited for the cells in the epithelium to decay, and then he injected testosterone or estrogen to see if they regrew. If he didn’t have the right microscope to analyze results, he wheedled for time at a local university and carried his samples there.
“These days it would be completely unacceptable,” Basson told Endpoints News, citing the ethical concerns of a high schooler doing unapproved animal experiments. “It just wasn’t as well appreciated in the 1970s.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,100+ biopharma pros reading Endpoints daily — and it's free.